Investment Summary

Aisling Capital and Eight Roads Invest In Promentis Pharmaceuticals

On January 1, 2016, private equity firms Aisling Capital and Eight Roads invested in life science company Promentis Pharmaceuticals

Investment Highlights
  • This is Aisling Capital’s 26th and Eight Roads’ 35th transaction in the Life Science sector.
  • This is Aisling Capital’s 34th and Eight Roads’ 54th transaction in the United States.
  • This is Aisling Capital’s 1st and Eight Roads’ 1st transaction in Wisconsin.

Investment Summary
Date 2016-01-01
Target Promentis Pharmaceuticals
Sector Life Science
Investor(s) Aisling Capital
Eight Roads
Deal Type Venture

Target

Promentis Pharmaceuticals

Milwaukee, Wisconsin, United States
Promentis Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of first-in-class therapies to treat central nervous system disorders of System XC. Promentis Pharmaceuticals is based in Milwaukee, Wisconsin.

Search 201,157 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Investor(S) 2

Investor

Aisling Capital

New York, New York, United States

Investor Investor Investor Investor Investor

Category Private Equity Firm
Founded 2000
PE ASSETS 1.8B USD
Size Large
Type Sector Focused
DESCRIPTION

Aisling Capital is a private investment firm focused on opportunities in the healthcare and medical technology sectors. The Firm specifically looks to invest in companies developing and commercializing innovative healthcare products, services, and technologies. Aisling Capital looks to commit $20 to $50 million per investment and prefers to be the lead investor. Aisling will consider investing in both public and private companies. Aisling Capital raised its first fund in 2000. The Firm is based in New York City.

DEAL STATS #
Overall 36 of 56
Sector (Life Science) 26 of 42
Type (Venture) 22 of 29
State (Wisconsin) 1 of 1
Country (United States) 34 of 52
Year (2016) 2 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-01-01 Prolacta Bioscience

Adelaide, Australia

Prolacta Bioscience is a biopharmaceutical company developing and marketing human milk-based nutritional products for premature infants in the neonatal intensive care unit. Prolacta Bioscience was founded in 1999 and is based in Adelaide, Australia.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2016-01-12 Syros Pharmaceuticals

Cambridge, Massachusetts, United States

Syros Pharmaceuticals is a biopharmaceutical company applying a pioneering approach to discover and develop medicines that control the expression of genes with the aim of treating cancer and other serious diseases.

Buy -
Investor

Eight Roads

Investor

Category Private Equity Firm
Founded 1969
Size Small
Type Sector Focused
DESCRIPTION

Eight Roads is a private investment firm focused on a variety of investment opportunities across the US, Europe, and Asia. The Firm is divided into several investment strategies including venture, principal investing, and real estate. Within the principal investments group, Eight Roads backs established growth businesses with long-term capital. Eight Roads does not have any sector preferences, but has experience in fintech, business services, and healthcare. Eight Roads is based in London.

DEAL STATS #
Overall 120 of 298
Sector (Life Science) 35 of 74
Type (Venture) 100 of 269
State (Wisconsin) 1 of 1
Country (United States) 54 of 124
Year (2016) 6 of 22
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-01-01 Compte Nickel

Charenton-Le-Pont, France

Compte Nickel is an alternative model of accounts without overdraft opened in 5 minutes at a partner tobacconist. This account allows customers to deposit and withdraw money, make transfers and direct debits. Compte Nickel is based in Charenton-Le-Pont, France.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2016-01-07 QuanCheng

Shanghai, China

QuanCheng is a SaaS corporate expense management startup, specializing in corporate expense management and vendor management. QuanCheng was founded in 2013 and is based in Shanghai, China.

Buy -
Mergr

Product

Company

Legal